Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 416858 versus enoxaparin for venous thromboembolism prevention after total knee arthroplasty
2012-001836-72Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2012
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fesomersen in venous thromboembolism (VTE) (2 arms), sponsored by Ionis Pharmaceuticals. Started Oct 2012; status: completed.
02
Drugs
fesomersen
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2012-001836-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001836-72.